Literature DB >> 10888087

Mid-term follow up of mitral valve reconstruction due to active infective endocarditis.

B K Podesser1, S Rödler, R Hahn, E Eigenbauer, M Vodrazka, A Moritz, G Laufer, P Simon, E Wolner.   

Abstract

BACKGROUND AND AIM OF THE STUDY: Mitral valve reconstruction in patients with acute endocarditis (AE) is a challenging operation which prompts the surgeon into immediate action. This report summarizes the mid-term results of 22 patients who required mitral valve reconstruction due to AE.
METHODS: Mean patient age was 46 years (range: 20-79 years); mean follow up was 46 months (range: 1-90 months). Preoperatively, >70% of patients had severe mitral regurgitation and were in NYHA functional class III. Surgical techniques used were annuloplasty (n = 16; 10 with Carpentier ring, five Wooler-Kay and one Frater); suture closure of the perforation (n = 1), patch closure of the perforation (n = 5), leaflet resection with primary closure (n = 2), leaflet resection with patch closure (n = 8), and chordal transfer (n = 3). Additional surgery included CABG (n = 3) and De Vega plasty (n = 4). Aortic valve replacement or reconstruction (n = 9) included one mechanical valve, one bioprosthesis, one reconstruction and six homografts. Patients were followed up annually in our outpatient department and/or by questionnaires.
RESULTS: Two patients died perioperatively due to either low output syndrome or uncontrolled sepsis. There were three reoperations; two of these were successful, and one patient subsequently died. In addition, one patient died six years after operation due to prostatic cancer, and one seven years later due to progressive heart failure. At the last follow up, 15 patients were in NYHA class I (68%) and five in class II (23%); no or only mild mitral insufficiency was seen on transthoracic echocardiography (91%). The estimated survival rate at 60 months was 87 +/- 12.7%, and 12 patients were followed up for >60 months. No incidence of recurrent valve infection occurred.
CONCLUSION: Mitral valve reconstruction in patients with AE shows a low incidence of valve-related complications with promising postoperative functional results and mid-term survival. On this basis, mitral valve reconstruction for mitral insufficiency secondary to AE may be recommended as a valve salvage treatment, when it is technically possible.

Entities:  

Mesh:

Year:  2000        PMID: 10888087

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  6 in total

1.  Repair for active infective atrioventricular valve endocarditis: 23-year single center experience.

Authors:  Michele Musci; Michael Hübler; Aref Amiri; Julia Stein; Susanne Kosky; Yuguo Weng; Miralem Pasic; Roland Hetzer
Journal:  Clin Res Cardiol       Date:  2011-06-25       Impact factor: 5.460

2.  Combined aortic and mitral valve repair in active infective endocarditis.

Authors:  Hiroichiro Yamaguchi; Kiyoyuki Eishi; Shiro Yamachika; Kazuyoshi Tanigawa; Kenta Izumi; Seiji Matsukuma
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-07

3.  Mitral valve repair for active culture positive infective endocarditis.

Authors:  G Doukas; M Oc; C Alexiou; A W Sosnowski; N J Samani; T J Spyt
Journal:  Heart       Date:  2005-06-10       Impact factor: 5.994

4.  Outcome of surgical management for active mitral native valve infective endocarditis: a collective review of 57 patients.

Authors:  Takashi Miura; Masayoshi Hamawaki; Shiro Hazama; Koji Hashizume; Tsuneo Ariyoshi; Mizuki Sumi; Akitsugu Furumoto; Nobuo Saito; Akira Tsuneto; Kiyoyuki Eishi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-02-13

5.  Role of mitral valve repair in active infective endocarditis: long term results.

Authors:  Carlo Rostagno; Enrico Carone; Pier Luigi Stefàno
Journal:  J Cardiothorac Surg       Date:  2017-05-18       Impact factor: 1.637

6.  Should more patients be offered repair for mitral valve endocarditis? a single-centre 15-year experience.

Authors:  Clarissa Ng Yin Ling; David Bleetman; Soumik Pal; Hing Chi Kristie Leung; Habib Khan; Donald Whitaker; Olaf Wendler; Ranjit Deshpande; Max Baghai
Journal:  J Cardiothorac Surg       Date:  2022-09-30       Impact factor: 1.522

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.